ESR1 and breast carcinoma: The interest to use the estrogen receptor-positive MCF-7 cell line as a model to evaluate the DOX/MO combinatory anticancer effect stemmed from the evidence that although DOX is among the most active chemotherapeutic drugs for the treatment of breast cancer; it has several limitations particularly in estrogen dependent breast cancer [16].